Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - Preparation is underway for expansion of Symvess into other countries, including in the Middle East DURHAM, N.C., March 17, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it submitted a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair. In response to surgeon request, Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval. “Surgeons, hospitals and patients in Israel have made an important contribution to the development of Symvess, and we are pleased to have taken an import
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma RepairGlobeNewswire
- Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Humacyte To Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 1/9/26 - Form SCHEDULE
- HUMA's page on the SEC website